{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:30:03Z","timestamp":1790775003306,"version":"4.1.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Liver cirrhosis due to nonalcoholic steatohepatitis (NASH) is a life-threatening condition with increasing incidence world-wide. Although its symptoms are unspecific, it can lead to decompensation events such as ascites, hepatic encephalopathy, variceal hemorrhage, and hepatocellular carcinoma (HCC). In addition, an increased risk for cardiovascular events has been demonstrated in patients with NASH. Pharmacological treatments for NASH cirrhosis are not yet available, one of the reasons being the lack in surrogate endpoints available in clinical trials of NASH cirrhosis. The feasibility of non-invasive prognostic biomarkers makes them interesting candidates as possible surrogate endpoints if their change following treatment would result in better outcomes for patients in future clinical trials of NASH cirrhosis. In this systematic literature review, a summary of the available literature on the prognostic performance of non-invasive biomarkers in terms of cardiovascular events, liver-related events, and mortality is outlined. Due to the scarcity of data specific for NASH cirrhosis, this review includes studies on NAFLD whose evaluation focuses on cirrhosis. Our search strategy identified the following non-invasive biomarkers with prognostic value in studies of NASH patients: NAFLD fibrosis score (NFS), Fibrosis-4 (FIB-4), aspartate aminotransferase (AST) to platelet ratio index (APRI), enhanced liver fibrosis (ELF\u2122), BARD (BMI, AST\/ALT (alanine aminotransferase) ratio, diabetes), Hepamet Fibrosis Score (HFS), liver enzymes (AST\u2009+\u2009ALT), alpha-fetoprotein, platelet count, neutrophil to lymphocyte ratio (NLR), Lysyl oxidase-like (LOXL) 2, miR-122, liver stiffness, MEFIB (liver stiffness measured with magnetic resonance elastography (MRE)\u2009+\u2009FIB-4), and PNPLA3 GG genotype. The aim of the present systematic literature review is to provide the reader with a summary of the non-invasive biomarkers with prognostic value in NASH cirrhosis and give an evaluation of their utility as treatment monitoring biomarkers in future clinical trials.<\/jats:p>","DOI":"10.1007\/s00109-024-02448-2","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T13:01:56Z","timestamp":1715864516000},"page":"841-858","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4899-7287","authenticated-orcid":false,"given":"Mattia","family":"Amoroso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3515-9033","authenticated-orcid":false,"given":"Salvador","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Moosmang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5984-576X","authenticated-orcid":false,"given":"Isabella","family":"Gashaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"2448_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/s0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW-S, Rinella M (2021) Non-alcoholic fatty liver disease. Lancet 397:2212\u20132224. https:\/\/doi.org\/10.1016\/s0140-6736(20)32511-3","journal-title":"Lancet"},{"key":"2448_CR2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","volume":"15","author":"VW-S Wong","year":"2018","unstructured":"Wong VW-S, Adams LA, de L\u00e9dinghen V et al (2018) Noninvasive biomarkers in NAFLD and NASH\u2014current progress and future promise. Nat Rev Gastroentero 15:461\u2013478. https:\/\/doi.org\/10.1038\/s41575-018-0014-9","journal-title":"Nat Rev Gastroentero"},{"key":"2448_CR3","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1056\/nejmoa044456","volume":"353","author":"RJ Groszmann","year":"2005","unstructured":"Groszmann RJ, Garcia-Tsao G, Bosch J et al (2005) Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. New Engl J Med 353:2254\u20132261. https:\/\/doi.org\/10.1056\/nejmoa044456","journal-title":"New Engl J Med"},{"key":"2448_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/s0168-8278(02)00420-8","volume":"38","author":"M Merli","year":"2003","unstructured":"Merli M, Nicolini G, Angeloni S et al (2003) Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 38:266\u2013272. https:\/\/doi.org\/10.1016\/s0168-8278(02)00420-8","journal-title":"J Hepatol"},{"key":"2448_CR5","doi-asserted-by":"publisher","first-page":"A2","DOI":"10.1016\/s0016-5085(08)80011-x","volume":"120","author":"G D\u2019Amico","year":"2001","unstructured":"D\u2019Amico G, Pasta L, Madonia S et al (2001) The incidence of esophageal varices in cirrhosis. Gastroenterology 120:A2. https:\/\/doi.org\/10.1016\/s0016-5085(08)80011-x","journal-title":"Gastroenterology"},{"key":"2448_CR6","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.3748\/wjg.v25.i28.3738","volume":"25","author":"DV Garbuzenko","year":"2019","unstructured":"Garbuzenko DV, Arefyev NO (2019) Current approaches to the management of patients with cirrhotic ascites. World J Gastroentero 25:3738\u20133752. https:\/\/doi.org\/10.3748\/wjg.v25.i28.3738","journal-title":"World J Gastroentero"},{"key":"2448_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.7861\/clinmed.2019-0250","volume":"20","author":"A Hussain","year":"2020","unstructured":"Hussain A, Patel PJ, Rhodes F et al (2020) Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment. Clin Med 20:313\u2013318. https:\/\/doi.org\/10.7861\/clinmed.2019-0250","journal-title":"Clin Med"},{"key":"2448_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S et al (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149:389-397.e10. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.043","journal-title":"Gastroenterology"},{"key":"2448_CR9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/hep.24491","volume":"54","author":"N Bhala","year":"2011","unstructured":"Bhala N, Angulo P, van der Poorten D et al (2011) The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 54:1208\u20131216. https:\/\/doi.org\/10.1002\/hep.24491","journal-title":"Hepatology"},{"key":"2448_CR10","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P et al (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61:1547\u20131554. https:\/\/doi.org\/10.1002\/hep.27368","journal-title":"Hepatology"},{"key":"2448_CR11","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/hep.30664","volume":"70","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal AJ, Harrison SA, Ratziu V et al (2019) The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data From the Simtuzumab Trials. Hepatology 70:1913\u20131927. https:\/\/doi.org\/10.1002\/hep.30664","journal-title":"Hepatology"},{"key":"2448_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","volume":"68","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez E, Chalasani N (2018) Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol 68:305\u2013315. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.013","journal-title":"J Hepatol"},{"key":"2448_CR13","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R (2019) Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156:1264-1281.e4. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.036","journal-title":"Gastroenterology"},{"key":"2448_CR14","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/hep.21972","volume":"47","author":"JA Talwalkar","year":"2008","unstructured":"Talwalkar JA, Yin M, Fidler JL et al (2008) Magnetic resonance imaging of hepatic fibrosis: Emerging clinical applications. Hepatology 47:332\u2013342. https:\/\/doi.org\/10.1002\/hep.21972","journal-title":"Hepatology"},{"key":"2448_CR15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/hep.510290347","volume":"29","author":"SH Caldwell","year":"1999","unstructured":"Caldwell SH, Oelsner DH, Iezzoni JC et al (1999) Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29:664\u2013669. https:\/\/doi.org\/10.1002\/hep.510290347","journal-title":"Hepatology"},{"key":"2448_CR16","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/hep.21103","volume":"43","author":"AJ Sanyal","year":"2006","unstructured":"Sanyal AJ, Banas C, Sargeant C et al (2006) Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43:682\u2013689. https:\/\/doi.org\/10.1002\/hep.21103","journal-title":"Hepatology"},{"key":"2448_CR17","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/hep.21327","volume":"44","author":"M Ekstedt","year":"2006","unstructured":"Ekstedt M, Franz\u00e9n LE, Mathiesen UL et al (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865\u2013873. https:\/\/doi.org\/10.1002\/hep.21327","journal-title":"Hepatology"},{"key":"2448_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/gast.2002.34168","volume":"123","author":"E Bugianesi","year":"2002","unstructured":"Bugianesi E, Leone N, Vanni E et al (2002) Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134\u2013140. https:\/\/doi.org\/10.1053\/gast.2002.34168","journal-title":"Gastroenterology"},{"key":"2448_CR19","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.cgh.2012.05.008","volume":"10","author":"FD Mendes","year":"2012","unstructured":"Mendes FD, Suzuki A, Sanderson SO et al (2012) Prevalence and Indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol H 10:1028-1033.e2. https:\/\/doi.org\/10.1016\/j.cgh.2012.05.008","journal-title":"Clin Gastroenterol H"},{"key":"2448_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","volume":"13","author":"S Singh","year":"2015","unstructured":"Singh S, Allen AM, Wang Z et al (2015) Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol H 13:643-654.e9. https:\/\/doi.org\/10.1016\/j.cgh.2014.04.014","journal-title":"Clin Gastroenterol H"},{"key":"2448_CR21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/apt.15660","volume":"51","author":"JB Henson","year":"2020","unstructured":"Henson JB, Simon TG, Kaplan A et al (2020) Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharm Therap 51:728\u2013736. https:\/\/doi.org\/10.1111\/apt.15660","journal-title":"Aliment Pharm Therap"},{"key":"2448_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100099","volume":"2","author":"L McSweeney","year":"2020","unstructured":"McSweeney L, Breckons M, Fattakhova G et al (2020) Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis. Jhep Reports 2:100099. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100099","journal-title":"Jhep Reports"},{"key":"2448_CR23","unstructured":"BEST (Biomarkers, EndpointS, and other Tools) Resource - NCBI Bookshelf. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/. Accessed 10 May 2023"},{"key":"2448_CR24","unstructured":"OVID webpage. https:\/\/ovidsp.dc1.ovid.com\/ovid-a\/ovidweb.cgi. Accessed 3 Jan 2023"},{"key":"2448_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"2448_CR26","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G et al (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846\u2013854. https:\/\/doi.org\/10.1002\/hep.21496","journal-title":"Hepatology"},{"key":"2448_CR27","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.cgh.2019.12.026","volume":"18","author":"F Baratta","year":"2020","unstructured":"Baratta F, Pastori D, Angelico F et al (2020) Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin Gastroenterol H 18:2324-2331.e4. https:\/\/doi.org\/10.1016\/j.cgh.2019.12.026","journal-title":"Clin Gastroenterol H"},{"key":"2448_CR28","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/hep.26156","volume":"57","author":"D Kim","year":"2013","unstructured":"Kim D, Kim WR, Kim HJ, Therneau TM (2013) Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57:1357\u20131365. https:\/\/doi.org\/10.1002\/hep.26156","journal-title":"Hepatology"},{"key":"2448_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202393","volume":"13","author":"N Peleg","year":"2018","unstructured":"Peleg N, Arbib OS, Issachar A et al (2018) Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease. PLoS ONE 13:e0202393. https:\/\/doi.org\/10.1371\/journal.pone.0202393","journal-title":"PLoS ONE"},{"key":"2448_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128774","volume":"10","author":"G Sebastiani","year":"2015","unstructured":"Sebastiani G, Alshaalan R, Wong P et al (2015) Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure gradient (HVPG) and histology in nonalcoholic steatohepatitis. PLoS ONE 10:e0128774. https:\/\/doi.org\/10.1371\/journal.pone.0128774","journal-title":"PLoS ONE"},{"key":"2448_CR31","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","volume":"145","author":"P Angulo","year":"2013","unstructured":"Angulo P, Bugianesi E, Bjornsson ES et al (2013) Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 145:782-789.e4. https:\/\/doi.org\/10.1053\/j.gastro.2013.06.057","journal-title":"Gastroenterology"},{"key":"2448_CR32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s12876-020-01509-3","volume":"20","author":"S Iritani","year":"2020","unstructured":"Iritani S, Akuta N, Kawamura Y et al (2020) Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. Bmc Gastroenterol 20:368. https:\/\/doi.org\/10.1186\/s12876-020-01509-3","journal-title":"Bmc Gastroenterol"},{"key":"2448_CR33","doi-asserted-by":"publisher","unstructured":"Xun Y, Guo J, Lou G et al (2014) Non\u2010alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6\u2010year overall mortality of Chinese patients with NAFLD. Clin Exp Pharmacol P 41:643\u2013649. https:\/\/doi.org\/10.1111\/1440-1681.12260","DOI":"10.1111\/1440-1681.12260"},{"key":"2448_CR34","doi-asserted-by":"publisher","unstructured":"Oh TJ, Kim K, Moon JH et al (2021) Liver fibrosis indices for the prediction of mortality in Korean subjects: a 16-year prospective cohort study. J Endocr Soc 5:bvab123.\u00a0https:\/\/doi.org\/10.1210\/jendso\/bvab123","DOI":"10.1210\/jendso\/bvab123"},{"key":"2448_CR35","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jhep.2021.05.008","volume":"75","author":"R Younes","year":"2021","unstructured":"Younes R, Caviglia GP, Govaere O et al (2021) Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J Hepatol 75:786\u2013794. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.008","journal-title":"J Hepatol"},{"key":"2448_CR36","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N et al (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43:1317\u20131325. https:\/\/doi.org\/10.1002\/hep.21178","journal-title":"Hepatology"},{"key":"2448_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.21669","volume":"46","author":"A Vallet-Pichard","year":"2007","unstructured":"Vallet-Pichard A, Mallet V, Nalpas B et al (2007) FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 46:32\u201336. https:\/\/doi.org\/10.1002\/hep.21669","journal-title":"Hepatology"},{"key":"2448_CR38","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah AG, Lydecker A, Murray K et al (2009) Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol H 7:1104\u20131112. https:\/\/doi.org\/10.1016\/j.cgh.2009.05.033","journal-title":"Clin Gastroenterol H"},{"key":"2448_CR39","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/hep4.1841","volume":"6","author":"JV Barbosa","year":"2022","unstructured":"Barbosa JV, Milligan S, Frick A et al (2022) Fibrosis-4 index as an independent predictor of mortality and liver-related outcomes in NAFLD. Hepatology Commun 6:765\u2013779. https:\/\/doi.org\/10.1002\/hep4.1841","journal-title":"Hepatology Commun"},{"key":"2448_CR40","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3390\/jcm11092466","volume":"11","author":"M Pons","year":"2022","unstructured":"Pons M, Rivera-Esteban J, Manzano R et al (2022) Non-invasive tests of liver fibrosis help in predicting the development of hepatocellular carcinoma among patients with NAFLD. J Clin Med 11:2466. https:\/\/doi.org\/10.3390\/jcm11092466","journal-title":"J Clin Med"},{"key":"2448_CR41","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","volume":"76","author":"M Rinella","year":"2021","unstructured":"Rinella M, Dufour J-F, Anstee QM et al (2021) Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study. J Hepatol 76:536\u2013548. https:\/\/doi.org\/10.1016\/j.jhep.2021.10.029","journal-title":"J Hepatol"},{"key":"2448_CR42","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"C Wai","year":"2003","unstructured":"Wai C, Greenson JK, Fontana RJ et al (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38:518\u2013526. https:\/\/doi.org\/10.1053\/jhep.2003.50346","journal-title":"Hepatology"},{"key":"2448_CR43","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/gut.2007.146019","volume":"57","author":"SA Harrison","year":"2008","unstructured":"Harrison SA, Oliver D, Arnold HL et al (2008) Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57:1441. https:\/\/doi.org\/10.1136\/gut.2007.146019","journal-title":"Gut"},{"key":"2448_CR44","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1053\/j.gastro.2004.08.052","volume":"127","author":"WMC Rosenberg","year":"2004","unstructured":"Rosenberg WMC, Voelker M, Thiel R et al (2004) Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 127:1704\u20131713. https:\/\/doi.org\/10.1053\/j.gastro.2004.08.052","journal-title":"Gastroenterology"},{"key":"2448_CR45","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1373\/jalm.2018.027359","volume":"3","author":"J Day","year":"2019","unstructured":"Day J, Patel P, Parkes J, Rosenberg W (2019) Derivation and performance of standardized enhanced liver fibrosis (ELF) test thresholds for the detection and prognosis of liver fibrosis. J Appl Lab Med 3:815\u2013826. https:\/\/doi.org\/10.1373\/jalm.2018.027359","journal-title":"J Appl Lab Med"},{"key":"2448_CR46","unstructured":"fda.gov. https:\/\/www.fda.gov\/media\/144267\/download. Accessed 3 Jan 2023"},{"key":"2448_CR47","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jpeds.2021.08.012","volume":"239","author":"S Gawrieh","year":"2021","unstructured":"Gawrieh S, Harlow KE, Pike F et al (2021) Relationship of enhanced liver fibrosis score with pediatric nonalcoholic fatty liver disease histology and response to vitamin E or metformin. J Pediatrics 239:161-167.e5. https:\/\/doi.org\/10.1016\/j.jpeds.2021.08.012","journal-title":"J Pediatrics"},{"key":"2448_CR48","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/nejmoa2028395","volume":"384","author":"PN Newsome","year":"2020","unstructured":"Newsome PN, Buchholtz K, Cusi K et al (2020) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. New Engl J Med 384:1113\u20131124. https:\/\/doi.org\/10.1056\/nejmoa2028395","journal-title":"New Engl J Med"},{"key":"2448_CR49","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/hep.31622","volume":"73","author":"R Loomba","year":"2021","unstructured":"Loomba R, Noureddin M, Kowdley KV et al (2021) Combination therapies including Cilofexor and Firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology 73:625\u2013643. https:\/\/doi.org\/10.1002\/hep.31622","journal-title":"Hepatology"},{"key":"2448_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","volume":"73","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Wong VW-S, Okanoue T et al (2020) Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol 73:26\u201339. https:\/\/doi.org\/10.1016\/j.jhep.2020.02.027","journal-title":"J Hepatol"},{"key":"2448_CR51","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1002\/hep.30590","volume":"71","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Rossi SJ, Paredes AH et al (2020) NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology 71:1198\u20131212. https:\/\/doi.org\/10.1002\/hep.30590","journal-title":"Hepatology"},{"key":"2448_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100563","volume":"5","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Ruane PJ, Freilich B et al (2023) A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. Jhep Reports 5:100563. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100563","journal-title":"Jhep Reports"},{"key":"2448_CR53","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/hep.32204","volume":"75","author":"AJ Sanyal","year":"2022","unstructured":"Sanyal AJ, Anstee QM, Trauner M et al (2022) Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology 75:1235\u20131246. https:\/\/doi.org\/10.1002\/hep.32204","journal-title":"Hepatology"},{"key":"2448_CR54","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cgh.2019.05.051","volume":"18","author":"J Ampuero","year":"2020","unstructured":"Ampuero J, Pais R, Aller R et al (2020) Development and validation of hepamet fibrosis scoring system\u2014a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis. Clin Gastroenterol H 18:216-225.e5. https:\/\/doi.org\/10.1016\/j.cgh.2019.05.051","journal-title":"Clin Gastroenterol H"},{"key":"2448_CR55","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/hep.31157","volume":"72","author":"Y Natarajan","year":"2020","unstructured":"Natarajan Y, Kramer JR, Yu X et al (2020) Risk of cirrhosis and hepatocellular cancer in patients with NAFLD and normal liver enzymes. Hepatology 72:1242\u20131252. https:\/\/doi.org\/10.1002\/hep.31157","journal-title":"Hepatology"},{"key":"2448_CR56","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2019.05.008","volume":"71","author":"GN Ioannou","year":"2019","unstructured":"Ioannou GN, Green P, Kerr KF, Berry K (2019) Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol 71:523\u2013533. https:\/\/doi.org\/10.1016\/j.jhep.2019.05.008","journal-title":"J Hepatol"},{"key":"2448_CR57","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/liv.12226","volume":"33","author":"S Verma","year":"2013","unstructured":"Verma S, Jensen D, Hart J, Mohanty SR (2013) Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int 33:1398\u20131405. https:\/\/doi.org\/10.1111\/liv.12226","journal-title":"Liver Int"},{"key":"2448_CR58","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00432-020-03331-6","volume":"146","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Zhu M, Li M (2020) Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma. J Cancer Res Clin 146:2439\u20132446. https:\/\/doi.org\/10.1007\/s00432-020-03331-6","journal-title":"J Cancer Res Clin"},{"key":"2448_CR59","doi-asserted-by":"publisher","first-page":"12870","DOI":"10.1038\/s41598-017-12834-1","volume":"7","author":"D-S Bai","year":"2017","unstructured":"Bai D-S, Zhang C, Chen P et al (2017) The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep-uk 7:12870. https:\/\/doi.org\/10.1038\/s41598-017-12834-1","journal-title":"Sci Rep-uk"},{"key":"2448_CR60","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.bpg.2014.08.007","volume":"28","author":"C Bosetti","year":"2014","unstructured":"Bosetti C, Turati F, Vecchia CL (2014) Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterology 28:753\u2013770. https:\/\/doi.org\/10.1016\/j.bpg.2014.08.007","journal-title":"Best Pract Res Clin Gastroenterology"},{"key":"2448_CR61","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12876-018-0900-1","volume":"18","author":"N Akuta","year":"2018","unstructured":"Akuta N, Kawamura Y, Arase Y et al (2018) Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. Bmc Gastroenterol 18:165. https:\/\/doi.org\/10.1186\/s12876-018-0900-1","journal-title":"Bmc Gastroenterol"},{"key":"2448_CR62","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.3390\/cancers13184567","volume":"13","author":"JS Lee","year":"2021","unstructured":"Lee JS, Sinn DH, Park SY et al (2021) Liver stiffness-based risk prediction model for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancers 13:4567. https:\/\/doi.org\/10.3390\/cancers13184567","journal-title":"Cancers"},{"key":"2448_CR63","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1111\/jgh.14989","volume":"35","author":"T Kogiso","year":"2020","unstructured":"Kogiso T, Sagawa T, Kodama K et al (2020) Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population. J Gastroen Hepatol 35:1579\u20131589. https:\/\/doi.org\/10.1111\/jgh.14989","journal-title":"J Gastroen Hepatol"},{"key":"2448_CR64","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrc.2016.52","volume":"16","author":"SB Coffelt","year":"2016","unstructured":"Coffelt SB, Wellenstein MD, de Visser KE (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16:431\u2013446. https:\/\/doi.org\/10.1038\/nrc.2016.52","journal-title":"Nat Rev Cancer"},{"key":"2448_CR65","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12935-020-1094-5","volume":"20","author":"J Zhao","year":"2020","unstructured":"Zhao J, Huang W, Wu Y et al (2020) Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: a systematic review and meta-analysis. Cancer Cell Int 20:15. https:\/\/doi.org\/10.1186\/s12935-020-1094-5","journal-title":"Cancer Cell Int"},{"key":"2448_CR66","doi-asserted-by":"publisher","first-page":"68837","DOI":"10.18632\/oncotarget.18575","volume":"8","author":"J Zhang","year":"2017","unstructured":"Zhang J, Zhang H-Y, Li J et al (2017) The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: a systematic review and meta-analysis. Oncotarget 8:68837\u201368846. https:\/\/doi.org\/10.18632\/oncotarget.18575","journal-title":"Oncotarget"},{"key":"2448_CR67","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.3748\/wjg.v21.i9.2807","volume":"21","author":"J-J Yang","year":"2015","unstructured":"Yang J-J, Hu Z-G, Shi W-X et al (2015) Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A meta-analysis. World J Gastroentero 21:2807\u20132815. https:\/\/doi.org\/10.3748\/wjg.v21.i9.2807","journal-title":"World J Gastroentero"},{"key":"2448_CR68","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000000639","volume":"94","author":"F Gao","year":"2015","unstructured":"Gao F, Li X, Geng M et al (2015) Pretreatment Neutrophil-lymphocyte ratio. Medicine 94:e639. https:\/\/doi.org\/10.1097\/md.0000000000000639","journal-title":"Medicine"},{"key":"2448_CR69","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1007\/s10620-021-07001-6","volume":"67","author":"NE Rich","year":"2022","unstructured":"Rich NE, Parvathaneni A, Sen A et al (2022) High neutrophil-lymphocyte ratio and delta neutrophil-lymphocyte ratio are associated with increased mortality in patients with hepatocellular cancer. Digest Dis Sci 67:2666\u20132676. https:\/\/doi.org\/10.1007\/s10620-021-07001-6","journal-title":"Digest Dis Sci"},{"key":"2448_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5185","author":"CE Thomas","year":"2022","unstructured":"Thomas CE, Yu Y, Luu HN et al (2022) Neutrophil-lymphocyte ratio in relation to risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Cancer Med-us. https:\/\/doi.org\/10.1002\/cam4.5185","journal-title":"Cancer Med-us"},{"key":"2448_CR71","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1136\/gutjnl-2016-312473","volume":"66","author":"N Ikenaga","year":"2017","unstructured":"Ikenaga N, Peng Z-W, Vaid KA et al (2017) Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut 66:1697. https:\/\/doi.org\/10.1136\/gutjnl-2016-312473","journal-title":"Gut"},{"key":"2448_CR72","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1042\/cs20170175","volume":"131","author":"P Dongiovanni","year":"2017","unstructured":"Dongiovanni P, Meroni M, Baselli GA et al (2017) Insulin resistance promotes Lysyl oxidase like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. Clin Sci 131:1301\u20131315. https:\/\/doi.org\/10.1042\/cs20170175","journal-title":"Clin Sci"},{"key":"2448_CR73","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.31236","volume":"72","author":"W Chen","year":"2020","unstructured":"Chen W, Yang A, Jia J et al (2020) Lysyl Oxidase (LOX) Family members: rationale and their potential as therapeutic targets for liver fibrosis. Hepatology 72:729\u2013741. https:\/\/doi.org\/10.1002\/hep.31236","journal-title":"Hepatology"},{"key":"2448_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183013","volume":"12","author":"CR Harlow","year":"2017","unstructured":"Harlow CR, Wu X, van Deemter M et al (2017) Targeting lysyl oxidase reduces peritoneal fibrosis. PLoS ONE 12:e0183013. https:\/\/doi.org\/10.1371\/journal.pone.0183013","journal-title":"PLoS ONE"},{"key":"2448_CR75","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41598-017-00270-0","volume":"7","author":"V Aumiller","year":"2017","unstructured":"Aumiller V, Strobel B, Romeike M et al (2017) Comparative analysis of lysyl oxidase (like) family members in pulmonary fibrosis. Sci Rep-uk 7:149. https:\/\/doi.org\/10.1038\/s41598-017-00270-0","journal-title":"Sci Rep-uk"},{"key":"2448_CR76","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1096\/fj.14-268425","volume":"30","author":"SB Liu","year":"2016","unstructured":"Liu SB, Ikenaga N, Peng Z et al (2016) Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice. Faseb J 30:1599\u20131609. https:\/\/doi.org\/10.1096\/fj.14-268425","journal-title":"Faseb J"},{"key":"2448_CR77","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.bbadis.2018.01.019","volume":"1864","author":"W Zhao","year":"2018","unstructured":"Zhao W, Yang A, Chen W et al (2018) Inhibition of lysyl oxidase-like 1 (LOXL1) expression arrests liver fibrosis progression in cirrhosis by reducing elastin crosslinking. Biochimica et Biophysica Acta Bba Mol Basis Dis 1864:1129\u20131137. https:\/\/doi.org\/10.1016\/j.bbadis.2018.01.019","journal-title":"Biochimica et Biophysica Acta Bba Mol Basis Dis"},{"key":"2448_CR78","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1111\/liv.13177","volume":"36","author":"EG Meissner","year":"2016","unstructured":"Meissner EG, McLaughlin M, Matthews L et al (2016) Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. Liver Int 36:1783\u20131792. https:\/\/doi.org\/10.1111\/liv.13177","journal-title":"Liver Int"},{"key":"2448_CR79","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","volume":"155","author":"SA Harrison","year":"2018","unstructured":"Harrison SA, Abdelmalek MF, Caldwell S et al (2018) Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology 155:1140\u20131153. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.006","journal-title":"Gastroenterology"},{"key":"2448_CR80","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/s0960-9822(02)00809-6","volume":"12","author":"M Lagos-Quintana","year":"2002","unstructured":"Lagos-Quintana M, Rauhut R, Yalcin A et al (2002) Identification of tissue-specific microRNAs from mouse. Curr Biol 12:735\u2013739. https:\/\/doi.org\/10.1016\/s0960-9822(02)00809-6","journal-title":"Curr Biol"},{"key":"2448_CR81","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1038\/onc.2009.211","volume":"28","author":"C Coulouarn","year":"2009","unstructured":"Coulouarn C, Factor VM, Andersen JB et al (2009) Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28:3526\u20133536. https:\/\/doi.org\/10.1038\/onc.2009.211","journal-title":"Oncogene"},{"key":"2448_CR82","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nature04303","volume":"438","author":"J Kr\u00fctzfeldt","year":"2005","unstructured":"Kr\u00fctzfeldt J, Rajewsky N, Braich R et al (2005) Silencing of microRNAs in vivo with \u2018antagomirs\u2019.\u00a0Nature 438:685\u2013689. https:\/\/doi.org\/10.1038\/nature04303","journal-title":"Nature"},{"key":"2448_CR83","doi-asserted-by":"publisher","first-page":"32015","DOI":"10.1074\/jbc.m109.016774","volume":"284","author":"S Bai","year":"2009","unstructured":"Bai S, Nasser MW, Wang B et al (2009) MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to Sorafenib*. J Biol Chem 284:32015\u201332027. https:\/\/doi.org\/10.1074\/jbc.m109.016774","journal-title":"J Biol Chem"},{"key":"2448_CR84","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jhep.2012.10.015","volume":"58","author":"J Trebicka","year":"2013","unstructured":"Trebicka J, Anadol E, Elfimova N et al (2013) Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol 58:234\u2013239. https:\/\/doi.org\/10.1016\/j.jhep.2012.10.015","journal-title":"J Hepatol"},{"key":"2448_CR85","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/labinvest.2010.126","volume":"90","author":"RT Marquez","year":"2010","unstructured":"Marquez RT, Bandyopadhyay S, Wendlandt EB et al (2010) Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 90:1727\u20131736. https:\/\/doi.org\/10.1038\/labinvest.2010.126","journal-title":"Lab Invest"},{"key":"2448_CR86","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12876-016-0557-6","volume":"16","author":"N Akuta","year":"2016","unstructured":"Akuta N, Kawamura Y, Suzuki F et al (2016) Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. Bmc Gastroenterol 16:141. https:\/\/doi.org\/10.1186\/s12876-016-0557-6","journal-title":"Bmc Gastroenterol"},{"key":"2448_CR87","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000519995","volume":"100","author":"N Akuta","year":"2022","unstructured":"Akuta N, Kawamura Y, Suzuki F et al (2022) Dynamics of circulating miR-122 predict liver cancer and mortality in Japanese patients with histopathologically confirmed NAFLD and severe fibrosis stage. Oncology 100:31\u201338. https:\/\/doi.org\/10.1159\/000519995","journal-title":"Oncology"},{"key":"2448_CR88","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s12072-016-9729-2","volume":"10","author":"N Akuta","year":"2016","unstructured":"Akuta N, Kawamura Y, Suzuki F et al (2016) Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan. Hepatol Int 10:647\u2013656. https:\/\/doi.org\/10.1007\/s12072-016-9729-2","journal-title":"Hepatol Int"},{"key":"2448_CR89","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.134","volume":"3","author":"C Caussy","year":"2020","unstructured":"Caussy C, Johansson L (2020) Magnetic resonance-based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Endocrinol Diabetes Metabolism 3:e00134. https:\/\/doi.org\/10.1002\/edm2.134","journal-title":"Endocrinol Diabetes Metabolism"},{"key":"2448_CR90","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","volume":"29","author":"L Sandrin","year":"2003","unstructured":"Sandrin L, Fourquet B, Hasquenoph J-M et al (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29:1705\u20131713. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2003.07.001","journal-title":"Ultrasound Med Biol"},{"key":"2448_CR91","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/j.gastro.2008.03.076","volume":"135","author":"L Huwart","year":"2008","unstructured":"Huwart L, Sempoux C, Vicaut E et al (2008) Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 135:32\u201340. https:\/\/doi.org\/10.1053\/j.gastro.2008.03.076","journal-title":"Gastroenterology"},{"key":"2448_CR92","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","volume":"150","author":"K Imajo","year":"2016","unstructured":"Imajo K, Kessoku T, Honda Y et al (2016) Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 150:626-637.e7. https:\/\/doi.org\/10.1053\/j.gastro.2015.11.048","journal-title":"Gastroenterology"},{"key":"2448_CR93","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1148\/radiol.2018170601","volume":"286","author":"P Kennedy","year":"2018","unstructured":"Kennedy P, Wagner M, Cast\u00e9ra L et al (2018) Quantitative elastography methods in liver disease: current evidence and future directions. Radiology 286:738\u2013763. https:\/\/doi.org\/10.1148\/radiol.2018170601","journal-title":"Radiology"},{"key":"2448_CR94","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/apt.16324","volume":"53","author":"JG Park","year":"2021","unstructured":"Park JG, Jung J, Verma KK et al (2021) Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharm Therap 53:1030\u20131037. https:\/\/doi.org\/10.1111\/apt.16324","journal-title":"Aliment Pharm Therap"},{"key":"2448_CR95","doi-asserted-by":"publisher","first-page":"175628482210938","DOI":"10.1177\/17562848221093869","volume":"15","author":"V Ajmera","year":"2022","unstructured":"Ajmera V, Nguyen K, Tamaki N et al (2022) Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease. Ther Adv Gastroenter 15:17562848221093868. https:\/\/doi.org\/10.1177\/17562848221093869","journal-title":"Ther Adv Gastroenter"},{"key":"2448_CR96","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32594","author":"T Gidener","year":"2022","unstructured":"Gidener T, Dierkhising RA, Mara KC et al (2022) Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD. Hepatology. https:\/\/doi.org\/10.1002\/hep.32594","journal-title":"Hepatology"},{"key":"2448_CR97","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/liv.14301","volume":"40","author":"S Shili-Masmoudi","year":"2020","unstructured":"Shili-Masmoudi S, Wong GL, Hiriart J et al (2020) Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. Liver Int 40:581\u2013589. https:\/\/doi.org\/10.1111\/liv.14301","journal-title":"Liver Int"},{"key":"2448_CR98","doi-asserted-by":"publisher","unstructured":"Loomba R, Huang DQ, Sanyal AJ et al (2022) Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut Gutjnl 327777. https:\/\/doi.org\/10.1136\/gutjnl-2022-327777","DOI":"10.1136\/gutjnl-2022-327777"},{"key":"2448_CR99","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/hep.24624","volume":"55","author":"RP Myers","year":"2012","unstructured":"Myers RP, Pomier-Layrargues G, Kirsch R et al (2012) Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 55:199\u2013208. https:\/\/doi.org\/10.1002\/hep.24624","journal-title":"Hepatology"},{"key":"2448_CR100","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/s2468-1253(19)30383-8","volume":"5","author":"PN Newsome","year":"2020","unstructured":"Newsome PN, Sasso M, Deeks JJ et al (2020) FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterology Hepatology 5:362\u2013373. https:\/\/doi.org\/10.1016\/s2468-1253(19)30383-8","journal-title":"Lancet Gastroenterology Hepatology"},{"key":"2448_CR101","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1136\/gutjnl-2020-322976","volume":"70","author":"J Jung","year":"2021","unstructured":"Jung J, Loomba RR, Imajo K et al (2021) MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut 70:1946\u20131953. https:\/\/doi.org\/10.1136\/gutjnl-2020-322976","journal-title":"Gut"},{"key":"2448_CR102","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/hep.24283","volume":"53","author":"S Sookoian","year":"2010","unstructured":"Sookoian S, Pirola CJ (2010) Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatol (Baltim, Md) 53:1883\u20131894. https:\/\/doi.org\/10.1002\/hep.24283","journal-title":"Hepatol (Baltim, Md)"},{"key":"2448_CR103","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/hepr.12840","volume":"47","author":"Y Seko","year":"2017","unstructured":"Seko Y, Sumida Y, Tanaka S et al (2017) Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis\/fibrosis progression. Hepatol Res 47:1083\u20131092. https:\/\/doi.org\/10.1111\/hepr.12840","journal-title":"Hepatol Res"},{"key":"2448_CR104","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/flgastro-2017-100865","volume":"9","author":"SD Silva","year":"2018","unstructured":"Silva SD, Li W, Kemos P et al (2018) Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. Frontline Gastroenterol 9:115. https:\/\/doi.org\/10.1136\/flgastro-2017-100865","journal-title":"Frontline Gastroenterol"},{"key":"2448_CR105","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.metabol.2018.09.005","volume":"92","author":"YC Chooi","year":"2019","unstructured":"Chooi YC, Ding C, Magkos F (2019) The epidemiology of obesity Metabolis 92:6\u201310. https:\/\/doi.org\/10.1016\/j.metabol.2018.09.005","journal-title":"The epidemiology of obesity Metabolis"},{"key":"2448_CR106","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4254\/wjh.v6.i5.263","volume":"6","author":"RJ Wong","year":"2014","unstructured":"Wong RJ, Ahmed A (2014) Obesity and non-alcoholic fatty liver disease: disparate associations among Asian populations. World J Hepatology 6:263\u2013273. https:\/\/doi.org\/10.4254\/wjh.v6.i5.263","journal-title":"World J Hepatology"},{"key":"2448_CR107","doi-asserted-by":"publisher","first-page":"628","DOI":"10.7326\/m16-1895","volume":"166","author":"UP Gujral","year":"2017","unstructured":"Gujral UP, Vittinghoff E, Mongraw-Chaffin M et al (2017) Cardiometabolic abnormalities among normal-weight persons from five racial\/ethnic groups in the United States: a cross-sectional analysis of two cohort studies. Ann Intern Med 166:628. https:\/\/doi.org\/10.7326\/m16-1895","journal-title":"Ann Intern Med"},{"key":"2448_CR108","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/dmso.s182331","volume":"12","author":"KB Szanto","year":"2019","unstructured":"Szanto KB, Li J, Cordero P, Oben JA (2019) Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease. Diabetes Metabolic Syndrome Obes Targets Ther 12:357\u2013367. https:\/\/doi.org\/10.2147\/dmso.s182331","journal-title":"Diabetes Metabolic Syndrome Obes Targets Ther"},{"key":"2448_CR109","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cgh.2022.01.015","volume":"21","author":"VW-S Wong","year":"2023","unstructured":"Wong VW-S, Tak WY, Goh GBB et al (2023) Performance of noninvasive tests of fibrosis among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. Clin Gastroenterol H 21:90-102.e6. https:\/\/doi.org\/10.1016\/j.cgh.2022.01.015","journal-title":"Clin Gastroenterol H"},{"key":"2448_CR110","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/cid\/ciad203","volume":"77","author":"G Sebastiani","year":"2023","unstructured":"Sebastiani G, Milic J, Kablawi D et al (2023) Fibroscan-Aspartate aminotransferase score predicts liver-related outcomes, but not extrahepatic events, in a multicenter cohort of people with human immunodeficiency virus. Clin Infect Dis 77:396\u2013404. https:\/\/doi.org\/10.1093\/cid\/ciad203","journal-title":"Clin Infect Dis"},{"key":"2448_CR111","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3390\/ijms17050774","volume":"17","author":"LC Bertot","year":"2016","unstructured":"Bertot LC, Adams LA (2016) The natural course of non-alcoholic fatty liver disease. Int J Mol Sci 17:774. https:\/\/doi.org\/10.3390\/ijms17050774","journal-title":"Int J Mol Sci"},{"key":"2448_CR112","doi-asserted-by":"publisher","unstructured":"Seval GC, Kabacam G, Yakut M et al (2020) The natural course of non-alcoholic fatty liver disease. Hepatology Forum 1:20\u201324. https:\/\/doi.org\/10.14744\/hf.2020.0008","DOI":"10.14744\/hf.2020.0008"},{"key":"2448_CR113","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jhep.2022.07.004","volume":"77","author":"AM Allen","year":"2022","unstructured":"Allen AM, Therneau TM, Ahmed OT et al (2022) Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. J Hepatol 77:1237\u20131245. https:\/\/doi.org\/10.1016\/j.jhep.2022.07.004","journal-title":"J Hepatol"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-024-02448-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-024-02448-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-024-02448-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T06:03:08Z","timestamp":1719554588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-024-02448-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":113,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2448"],"URL":"https:\/\/doi.org\/10.1007\/s00109-024-02448-2","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"9 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.A., S.A., S.M. and I.G. are employed at Boehringer Ingelheim.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}